SEC Form 4 · accession 0001144204-18-013884
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Rubin
Officer — Executive Chairman · Director
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 4:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $0.97 | Mar 7, 2018 | A | 170,000 | A | — | Mar 7, 2028 | Common Stock | 170,000 | 170,000 | D |
Explanation of responses
- F1The options vest as to 25% on the grant date and 25% on each of the three month, six month and nine month anniversaries of the grant date.